MedTrace Logo

Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries

NCT00352222 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-09-29

No results posted yet for this study

Summary

To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).

Conditions

  • Arterial Occlusive Disease
  • Intermittent Claudication
  • Atherosclerotic Disease
  • Thrombosis

Interventions

DEVICE

stent implantation

Sponsors & Collaborators

  • KIKA

    collaborator UNKNOWN

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Luc Stockx, MD · Limburgs Vaatcentrum Ziekenhuis Oost-Limburg, Belgium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-07-31
Completion
2007-02-28

Countries

  • Belgium
  • Canada
  • Czechia
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352222 on ClinicalTrials.gov